Finnland -
Finnisch -
Fimea (Suomen lääkevirasto)
agomelatine mylan 25 mg tabletti, kalvopäällysteinen
mylan ab - agomelatine citric acid cocrystal - tabletti, kalvopäällysteinen - 25 mg - agomelatiini
Finnland -
Finnisch -
Fimea (Suomen lääkevirasto)
agomelatine stada 25 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - agomelatine citric acid cocrystal - tabletti, kalvopäällysteinen - 25 mg - agomelatiini
Finnland -
Finnisch -
Fimea (Suomen lääkevirasto)
agomelatine anpharm 25 mg tabletti, kalvopäällysteinen
anpharm przedsiebiorstwo farmaceutyczne s.a. - agomelatine - tabletti, kalvopäällysteinen - 25 mg - agomelatiini
Europäische Union -
Finnisch -
EMA (European Medicines Agency)
voraxaze
serb sas - glucarpidase - metabolic side effects of drugs and substances - kaikki muut terapeuttiset tuotteet - voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.
Europäische Union -
Finnisch -
EMA (European Medicines Agency)
riltrava aerosphere
astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - keuhkosairaus, krooninen obstruktiivinen - obstruktiivisten hengitystiesairauksien lääkkeet, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.
Europäische Union -
Finnisch -
EMA (European Medicines Agency)
amversio
serb sa - betaine - homokystinuria - muut ruuansulatuselimistön sairauksien ja aineenvaihduntasairauksien lääkkeet, - amversio is indicated as adjunctive treatment of homocystinuria, involving deficiencies or defects in:• cystathionine beta-synthase (cbs),• 5,10 methylene tetrahydrofolate reductase (mthfr),• cobalamin cofactor metabolism (cbl).
Europäische Union -
Finnisch -
EMA (European Medicines Agency)
quviviq
idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - unihäiriöiden ja ylläpidon häiriöt - psyykenlääkkeiden - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.
Finnland -
Finnisch -
Fimea (Suomen lääkevirasto)
xefal 500 mg kapseli, kova
antibiotice sa - cefalexin monohydrate - kapseli, kova - 500 mg - kefaleksiini
Europäische Union -
Finnisch -
EMA (European Medicines Agency)
mounjaro
eli lilly nederland b.v. - tirzepatide - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes. for study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4. 4, 4. 5 ja 5.